Theralase® Grants Stock Options
November 21 2022 - 6:00AM
Theralase® Technologies Inc. (“
Theralase®” or the
“
Company”) (
TSXV: TLT)
(
OTCQB: TLTFF), a clinical stage pharmaceutical
company focused on the research and development of light activated
Photo Dynamic Compounds (“
PDCs”) and their
associated drug formulations, used to destroy various cancers,
bacteria and viruses, safely and effectively, announces the grant
of stock options.
The Company has granted an aggregate of
7,860,000 stock options to directors, officers, employees &
advisory board members pursuant to the Company’s stock option plan.
The options granted, are exercisable at a price of CDN$0.25 per
share and vest over a three-year period and expire five years from
the date of the grant. The stock option plan was last approved by
the shareholders of the Company at the Annual General and Special
Meeting of Shareholders held on June 28, 2022.
About Theralase® Technologies
Inc.Theralase® is a clinical stage pharmaceutical company
dedicated to the research and development of light activated
compounds and their associated drug formulations with a primary
objective of efficacy and a secondary objective of safety in the
destruction of various cancers, bacteria and viruses.Additional
information is available
at www.theralase.com and www.sedar.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward Looking Statements
This news release contains "forward-looking
statements" within the meaning of applicable Canadian securities
laws. Such statements include, but are not limited to, statements
regarding the Company's proposed development plans with respect to
Photo Dynamic Compounds and their drug formulations. Forward
looking statements may be identified by the use of the words
"may", "should",
"will", "anticipates",
"believes", "plans",
"expects", "estimate",
"potential for" and similar expressions including
statements related to the current expectations of Company's
management for future research, development and commercialization
of the Company’s Photo Dynamic Compounds and their drug
formulations, including preclinical research, clinical studies and
regulatory approvals.
These statements involve significant risks,
uncertainties and assumptions; including, the ability of the
Company to: adequately fund and secure the requisite regulatory
approvals to successfully complete a Phase II NMIBC clinical study
in a timely fashion to implement its development plans. Other risks
include: the ability of the Company to successfully commercialize
its drug formulations, the risk that access to sufficient capital
to fund the Company’s operations may not be available or may not be
available on terms that are commercially favorable to the Company,
the risk that the Company’s drug formulations may not be effective
against the conditions tested in its clinical studies, the risk
that the Company’s fails to comply with the term of license
agreements with third parties and as a result loses the right to
use key intellectual property in its business, the Company’s
ability to protect its intellectual property, the timing and
success of submission, acceptance and approval of regulatory
filings, and the impacts of public health crises, such as COVID-19.
Many of these factors that will determine actual results are beyond
the Company's ability to control or predict.
Readers should not unduly rely on these forward-
looking statements, which are not a guarantee of future
performance. There can be no assurance that forward-looking
statements will successfully come to fruition, as such
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results or
future events to differ materially from the forward-looking
statements.
Although the forward-looking statements
contained in the press release are based upon what management
currently believes to be reasonable assumptions, the Company cannot
assure prospective investors that actual results, performance or
achievements will be consistent with these forward-looking
statements.
All forward-looking statements are made as of
the date hereof and are subject to change. Except as required by
law, the Company assumes no obligation to update such
statements.
For More Information:1.866.THE.LASE
(843.5273)416.699.LASE (5273)www.theralase.com
Kristina Hachey, CPAChief Financial
Officerkhachey@theralase.com416.699.LASE (5273) x 224
Theralase Technologies (TSXV:TLT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Theralase Technologies (TSXV:TLT)
Historical Stock Chart
From Aug 2023 to Aug 2024